T1	Participants 881 927	828 patients were randomized to IM400 or IM800
T2	Participants 929 978	Seven hundred eighty-four patients were evaluable
T3	Participants 1005 1083	One hundred ten patients (29 %) on IM400 and 83 (21 %) on IM800 were ≥65 years
T4	Participants 1274 1507	Older patients on IM800 achieved major molecular remission and deep molecular remission as fast as younger patients, in contrast to standard dose imatinib with which older patients achieved remissions much later than younger patients
T5	Participants 494 724	Patients randomized to imatinib 400 mg/day (IM400) or imatinib 800 mg/day (IM800) and stratified according to age (≥65 years vs. <65 years) were compared regarding dose, response, adverse events, rates of progression, and survival
T6	Participants 418 492	newly diagnosed BCR-ABL-positive chronic myeloid leukemia in chronic phase
